SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla surges on the buzz of plan to re-start supplying anti-HIV drugs to Naco

13 Jan 2015 Evaluate

Cipla is currently trading at Rs. 643.25, up by 12.25 points or 1.94% from its previous closing of Rs. 631.00 on the BSE.

The scrip opened at Rs. 629.00 and has touched a high and low of Rs. 643.80 and Rs. 629.00 respectively. So far 36748 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 671.95 on 31-Oct-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014.

Last one week high and low of the scrip stood at Rs. 643.80 and Rs. 604.80 respectively. The current market cap of the company is Rs. 51471.27 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.67% and 27.38% respectively.

Cipla is reportedly planning to re-start supplying anti-HIV drugs to the National Aids Control Organisation (Naco) in the next two months.

The Mumbai-based drug company had, during the second half of last year, stopped bidding for Naco tenders. The company had participated in the Naco’s paediatric tenders, which were being evaluated.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

 

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×